MEDISEARCHER NEWS
Australia · Menopause & prescription access · 11 November 2026
In brief
- Australia’s Therapeutic Goods Administration (TGA) has extended shortages of four Estradot hormone replacement therapy (HRT) patch strengths until an estimated 30 June 2027.
- Estradot 25, 50, 75 and 100 microgram patches are affected. The shortage of Estradot 37.5 has been resolved.
- The expected return date for Estraderm MX 100 patches is 30 November 2026.
- Pharmacists can make certain substitutions without obtaining a new prescription under special shortage arrangements.
- Overseas-registered estradiol patches have also been authorised for supply in Australia.
- Some substitutions can affect Pharmaceutical Benefits Scheme (PBS) subsidies and patient costs.
- The June 2027 dates are estimates, not guaranteed dates when every pharmacy will have stock.
Women in Australia who rely on hormone replacement therapy patches face a longer period of disrupted access after the country’s medicines regulator extended shortages of several widely used estradiol products into mid-2027.
In an update published on 11 November 2026, the Therapeutic Goods Administration (TGA) confirmed that shortages affecting Estradot 25, 50, 75 and 100 microgram patches are now expected to continue until 30 June 2027.
The previous estimated return date for these strengths was 31 December 2026, meaning the latest announcement extends the expected disruption by approximately six months.
The shortage affects medicines used in menopausal hormone therapy, including treatment of symptoms associated with perimenopause and menopause.
Although several alternative products are available, patients may need to use different brands or patch strengths, and the cost of some substitutions can differ depending on how the medicine is dispensed.
Which HRT patches are affected by the shortage?
The TGA’s updated shortage information identifies four Estradot strengths with estimated return-to-normal-supply dates of 30 June 2027.
| HRT patch | Current supply status | Estimated return to normal supply |
|---|---|---|
| Estradot 25 micrograms | Shortage / limited availability | 30 June 2027 |
| Estradot 37.5 micrograms | Shortage resolved | Not applicable |
| Estradot 50 micrograms | Shortage / limited availability | 30 June 2027 |
| Estradot 75 micrograms | Shortage / limited availability | 30 June 2027 |
| Estradot 100 micrograms | Shortage / limited availability | 30 June 2027 |
| Estraderm MX 100 micrograms | Shortage | 30 November 2026 |
| Estraderm MX 25, 50 and 75 micrograms | Shortages resolved | Not applicable |
| Estalis Sequi 50/140 and 50/250 | Shortages resolved | Not applicable |
| Estalis Continuous 50/140 and 50/250 | Shortages resolved | Not applicable |
Source: Therapeutic Goods Administration, updated 11 November 2026. Supply estimates can change, and local pharmacy availability may differ from the national shortage status.
The fact that some shortages have been resolved does not necessarily mean every pharmacy has immediate access to every product.
Patients can check the latest information through the TGA’s Medicine Shortages Reports Database.
Why are HRT patches in short supply?
The TGA describes the ongoing shortage of hormone replacement therapy patches as a global supply problem involving several contributing factors.
Manufacturing issues have reduced the availability of some products. Demand has consequently shifted towards alternative brands and strengths, creating further pressure on supplies.
The affected medicines include estradiol patches and combination estradiol/norethisterone products supplied by companies including Sandoz and Juno Pharmaceuticals.
Estradiol is a form of oestrogen used in menopausal hormone therapy. Transdermal patches deliver the hormone through the skin over time.
Patients may be prescribed patches for several reasons, including the management of troublesome menopausal symptoms. For some, patches are preferable to other formulations because of individual medical considerations or treatment preferences.
The shortage therefore creates more than a simple inconvenience: patients may need help maintaining their prescribed treatment while supplies remain unpredictable.
Can Australian pharmacists substitute another HRT patch?
Yes, in specified circumstances.
The TGA has introduced a Serious Scarcity Substitution Instrument (SSSI) allowing pharmacists to substitute certain estradiol-containing transdermal patches without first obtaining a new prescription.
Under the permitted arrangements, a pharmacist may supply:
- an alternative brand of estradiol patch delivering the same amount of hormone per day; or
- two patches of half the prescribed strength, where the substitution meets the applicable requirements.
For example, if a patient has been prescribed a 50 microgram estradiol patch and that strength is unavailable, an appropriate substitution may involve two 25 microgram patches.
Such substitutions are subject to the instrument’s specific conditions and the pharmacist’s professional assessment. They are not an invitation for patients to change their own treatment.
The TGA instructs pharmacists to prioritise the prescribed formulation and strength where possible, followed by an appropriate same-strength alternative, and then a permitted lower-strength combination.
Patients should receive clear instructions about the replacement product, including how many patches to apply and how often to change them.
Imported HRT patches are also available
To reduce the impact of the shortage, the TGA has authorised overseas-registered estradiol patches under section 19A of the Therapeutic Goods Act 1989.
Section 19A allows certain medicines that are not registered in Australia to be supplied under specific circumstances, including shortages of registered products.
The TGA says pharmacists can order approved overseas alternatives through the relevant approval holders.
Patients should not assume that an overseas-registered alternative is an unregulated product. These particular medicines are supplied through an Australian regulatory authorisation intended to address the shortage.
However, overseas-registered patches may differ from familiar Australian products in packaging, patch appearance, adhesives or pack sizes.
The current list of authorised products can be checked through the TGA’s Section 19A approvals database by searching for estradiol.
Will replacement HRT patches cost more?
They can, depending on the product and how it is dispensed.
The TGA confirms that approved overseas-registered HRT alternatives can be subsidised through Australia’s Pharmaceutical Benefits Scheme (PBS).
However, PBS eligibility does not automatically apply to every substitution made under the shortage arrangements.
Two specific exceptions are particularly important.
Estraderm MX 75
The TGA states that Estraderm MX 75 microgram patches are not PBS-listed.
If a pharmacist substitutes this product for a scarce PBS-listed medicine, the patient may not receive the usual PBS subsidy.
This can result in a higher out-of-pocket cost and may also affect how subsequent repeats are dispensed.
Imported Estramon patches
The overseas-registered Estramon 25, 50, 75 and 100 microgram patches have different pack sizes from Australian-registered Estradot and Estraderm products.
According to the TGA, Estramon packs contain 24 patches, compared with eight patches in the relevant Australian-registered packs.
Because of this difference, Estramon is not currently PBS-subsidised when supplied under the SSSI substitution process.
A new prescription is required for Estramon to be PBS-subsidised.
This distinction matters for patients who are offered an imported alternative and want to avoid unexpectedly paying the private price.
Before accepting a replacement, patients can ask their pharmacist whether it will be PBS-subsidised and whether a new prescription would provide a more suitable option.
Can two lower-strength patches replace one stronger patch?
In some circumstances, yes.
The TGA’s shortage arrangements permit a pharmacist to dispense two packs of patches at half the prescribed strength to provide an equivalent daily estradiol dose, provided the specific substitution conditions are satisfied.
For example, two 25 microgram patches may be used instead of one 50 microgram patch where the substitution is permitted and clinically appropriate.
The pharmacist must provide enough patches to maintain the intended duration of treatment and explain how the replacement should be used.
Patients should not independently double the number of patches they apply, combine different strengths or alter their prescribed dose.
The TGA also advises patients not to cut estradiol patches to create a different dose. Cutting a patch may change how the medicine is delivered through the skin.
What should patients do if their Estradot patches are unavailable?
Patients affected by the shortage can take several practical steps to maintain continuity of care.
- Speak to the dispensing pharmacist. Ask whether the prescribed strength is available or whether a permitted alternative brand or strength can be supplied.
- Ask about overseas-registered alternatives. Pharmacists may be able to order authorised imported estradiol patches.
- Check the PBS cost before accepting a substitute. Some replacements may require a new prescription to receive a subsidy.
- Confirm the application instructions. Different products may have different schedules, and some substitutions involve more than one patch.
- Contact the prescriber if an appropriate patch is unavailable. A clinician can assess whether another HRT formulation is suitable.
The TGA also advises patients to tell their pharmacist if they have previously experienced skin reactions to patches or adhesive bandages. Different products can use different adhesive ingredients.
Patients should avoid changing or stopping prescribed hormone therapy solely because their usual brand is temporarily unavailable without discussing appropriate options with a healthcare professional.
Are there alternatives to HRT patches?
Yes. Other forms of menopausal hormone therapy may be appropriate for some patients.
The TGA identifies alternatives including:
- oral hormone therapy tablets;
- topical hormone gels; and
- other formulations, including vaginal preparations for appropriate indications.
These products are not necessarily interchangeable with estradiol patches.
The appropriate alternative depends on the patient’s symptoms, medical history, treatment goals, other medicines and whether systemic or local hormone treatment is required.
In particular, vaginal treatments used for local menopausal symptoms should not be assumed to provide the same systemic effects as an estradiol patch.
Patients who cannot obtain their usual patches should discuss suitable alternatives with their prescriber rather than switching formulations independently.
Does the June 2027 date mean patches will be unavailable until then?
No. The TGA’s estimated return-to-normal-supply date does not mean that every affected product will be completely unavailable throughout the shortage.
Some stock may continue to reach pharmacies, and availability may fluctuate between brands, strengths and locations.
The date represents the regulator’s current estimate for when normal supply may resume.
It is also subject to change as manufacturers provide updated information.
For patients, this means their usual patches may sometimes be available even while a national shortage remains active. Conversely, a product whose shortage is officially resolved may not immediately be stocked by every pharmacy.
Why this shortage matters beyond Australia
Australia’s extended HRT patch shortage illustrates the vulnerability of medicine supply chains when manufacturing problems affect products with limited interchangeable alternatives.
The TGA explicitly describes the disruption as global, rather than an issue confined to the Australian market.
However, medicine availability, permitted substitutions and reimbursement rules vary between countries. Australia’s Section 19A and SSSI arrangements are specific to its regulatory system and should not be assumed to apply in the United Kingdom, European Union or elsewhere.
The latest extension also highlights the importance of clear information about the difference between a medicine being clinically substitutable and a particular replacement being eligible for public subsidy.
Frequently asked questions
When will the Estradot shortage end in Australia?
The TGA currently estimates that normal supply of Estradot 25, 50, 75 and 100 microgram patches will return by 30 June 2027. These are estimates and may change.
Which Estradot patches are affected?
Estradot 25, 50, 75 and 100 microgram patches remain affected. The TGA lists the shortage of Estradot 37.5 as resolved.
Is Estraderm MX also in shortage?
The TGA lists Estraderm MX 100 as affected until an estimated 30 November 2026. Shortages of Estraderm MX 25, 50 and 75 are listed as resolved.
Can my pharmacist give me another brand without a new prescription?
In certain circumstances, yes. Australia’s Serious Scarcity Substitution Instrument allows pharmacists to supply specified alternative estradiol patch brands or strengths without obtaining a new prescription, subject to the applicable requirements.
Are imported HRT patches covered by the PBS?
Some authorised overseas-registered alternatives are PBS-subsidised, but eligibility depends on the product and dispensing arrangement. Imported Estramon patches, for example, require a new prescription to receive PBS subsidy rather than being supplied under the shortage substitution process.
Can I cut an HRT patch in half if my usual dose is unavailable?
The TGA advises against cutting estradiol patches to make an equivalent dose because this may affect absorption. Patients should ask a pharmacist or prescriber about an appropriate replacement.
Can I switch from HRT patches to tablets or gels?
Other hormone therapy formulations are available, but they are not automatically equivalent. A healthcare professional should assess which alternative, if any, is suitable for the patient’s circumstances.
What happens next?
The TGA says it will continue monitoring estradiol-containing and combination HRT patch supplies and work with manufacturers and healthcare professionals to update shortage advice.
The immediate priority for patients is continuity of treatment, including access to appropriate replacement products and clear information about any additional costs.
The next significant milestones are the estimated return of Estraderm MX 100 supply on 30 November 2026 and the extended Estradot supply dates in June 2027.
Those dates may be revised as the global supply situation changes.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviewed the TGA’s 11 November 2026 shortage update, affected product strengths, authorised substitution arrangements, imported alternatives and PBS reimbursement exceptions. The article distinguishes estimated supply dates from guaranteed pharmacy availability.
Last reviewed: 11 November 2026
Sources and verification
This article is based primarily on official Australian medicines-regulator information, including the TGA’s updated shortage guidance and medicines shortage reporting system.
- Therapeutic Goods Administration: About the shortage of transdermal HRT patches — updated 11 November 2026
- Therapeutic Goods Administration: Medicine Shortages Reports Database
- Therapeutic Goods Administration: Section 19A approvals database
- Australasian Menopause Society: Menopausal hormone therapy shortages and supply information
This article is for general informational purposes and does not replace individual medical advice. Hormone replacement therapy is prescription treatment. Patients should discuss medicine shortages, alternative products, dosing instructions and treatment changes with an appropriate healthcare professional. Supply dates and subsidy arrangements may change.